Madrigal Pharmaceuticals Inc. announced that the European Commission (EC) has granted conditional marketing authorization for Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic MASH with moderate to… read more.
Investigators report that two out of three women of reproductive age in the USA have at least one modifiable risk factor for birth defects. The findings were published… read more.
Bristol Myers Squibb announced the presentation of new clinical and real-world data from its cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place August 29… read more.
BeOne Medicines Ltd. announced that the European Commission has approved a new film-coated tablet formulation of Brunkinsa (zanubrutinib) for all approved indications. “Developed to meet the real-world needs… read more.
Many direct to consumer menopause services are unnecessary and do not improve care, warn experts in The BMJ today. They argue that the sharp rise in commercial services… read more.
The European Regulation list on mandatory labelling of foods includes 14 allergenic foods. Research published in Clinical & Experimental Allergy has identified eight additional foods frequently involved in… read more.
In its latest (Q2) earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly costs due to lower… read more.
In a large-scale multinational study involving over 400,000 women and men aged 37 to 70 years from six European countries, researchers from the University of Vienna, in collaboration… read more.
Thanks to new advances in cancer care, more and more people are surviving cancer, with a projected total of 22.5 million survivors by 2032. The need for proper… read more.
Precigen, Inc. announced that the FDA has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). Papzimeosis the first and only FDA-approved therapy… read more.
The evidence supporting the health benefits of breastfeeding is overwhelming, yet many women taking medicines are being advised to stop, often unnecessarily, according to a new study from… read more.
Iovance Biotherapeutics Inc. announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Amtagvi (lifileucel), a tumor-derived autologous T cell immunotherapy. Amtagvi is indicated for… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
